GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cyclically Adjusted PB Ratio

Biogen (MEX:BIIB) Cyclically Adjusted PB Ratio : 3.06 (As of Jul. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Cyclically Adjusted PB Ratio?

As of today (2024-07-20), Biogen's current share price is MXN4026.63. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was MXN1,316.86. Biogen's Cyclically Adjusted PB Ratio for today is 3.06.

The historical rank and industry rank for Biogen's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:BIIB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.41   Med: 7.19   Max: 16.44
Current: 2.79

During the past years, Biogen's highest Cyclically Adjusted PB Ratio was 16.44. The lowest was 2.41. And the median was 7.19.

MEX:BIIB's Cyclically Adjusted PB Ratio is ranked worse than
64.33% of 743 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs MEX:BIIB: 2.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's adjusted book value per share data for the three months ended in Mar. 2024 was MXN1,743.638. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN1,316.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biogen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted PB Ratio Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.21 4.62 3.93 3.96 3.32

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 3.81 3.35 3.32 2.68

Competitive Comparison of Biogen's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.



Biogen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biogen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4026.63/1316.86
=3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1743.638/131.7762*131.7762
=1,743.638

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201406 525.123 100.560 688.137
201409 592.885 100.428 777.953
201412 679.701 99.070 904.095
201503 756.111 99.621 1,000.164
201506 838.828 100.684 1,097.867
201509 801.505 100.392 1,052.074
201512 737.261 99.792 973.556
201603 811.526 100.470 1,064.391
201606 962.464 101.688 1,247.244
201609 1,076.865 101.861 1,393.126
201612 1,158.761 101.863 1,499.048
201703 1,009.991 102.862 1,293.894
201706 990.456 103.349 1,262.890
201709 1,103.630 104.136 1,396.565
201712 1,171.201 104.011 1,483.846
201803 1,210.011 105.290 1,514.402
201806 1,195.974 106.317 1,482.371
201809 1,278.045 106.507 1,581.271
201812 1,298.339 105.998 1,614.090
201903 1,374.346 107.251 1,688.627
201906 1,346.380 108.070 1,641.729
201909 1,519.005 108.329 1,847.778
201912 1,444.620 108.420 1,755.823
202003 1,758.516 108.902 2,127.891
202006 1,648.948 108.767 1,997.770
202009 1,544.289 109.815 1,853.123
202012 1,396.656 109.897 1,674.717
202103 1,449.899 111.754 1,709.661
202106 1,435.462 114.631 1,650.156
202109 1,459.902 115.734 1,662.259
202112 1,520.576 117.630 1,703.448
202203 1,517.596 121.301 1,648.651
202206 1,644.979 125.017 1,733.920
202209 1,784.578 125.227 1,877.916
202212 1,813.927 125.222 1,908.872
202303 1,717.429 127.348 1,777.151
202306 1,712.839 128.729 1,753.388
202309 1,741.144 129.860 1,766.843
202312 1,733.669 129.419 1,765.240
202403 1,743.638 131.776 1,743.638

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (MEX:BIIB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biogen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines